The pricing of Longboard Pharmaceuticals' public offering is a common equity action that can have a neutral to slightly negative short-term impact on the stock price due to potential dilution of existing shares. However, the capital raised can be very beneficial for the company's future if used effectively for growth or operational improvements. The impact score is neutral because the negative effect of dilution may be offset by the positive use of the raised capital.